Companies · Medical Devices
MENLO PARK · Medical Devices · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on Prescient Surgical, Inc. — recommendation, valuation, rhythm, risks.→Prescient Surgical, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the medical devices sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Prescient Surgical, Inc. is one of 233 Medical Devices companies tracked from MENLO PARK. By capital raised it ranks in the upper tier (ahead of 85% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the medical devices sector profile. Directional, not a quoted figure.
Benchmarked against 233 companies in Medical Devices. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 85% of sector peers (real $). Modeled value above 32% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #17 of 17.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Reliant Immune Diagnostics, Inc. | Series A | $10.9M | $262.4M | 5.31× |
| Pristine Surgical LLC | Series A | $14.2M | $201.7M | 4.08× |
| Predictive Health Diagnostics Co. | Series A | $8.3M | $154.8M | 3.13× |
| Juno Diagnostics, Inc. | Series A | $6.3M | $107.9M | 2.18× |
| Allotrope Medical Inc. | Series A | $5.0M | $93.6M | 1.90× |
| Surgical Innovation Associates Inc. | Series A | $8.9M | $86.9M | 1.76× |
| CAIRA Surgical Corp | Series A | $5.2M | $85.4M | 1.73× |
| Sandstone Diagnostics Inc | Series A | $14.0M | $52.0M | 1.05× |
| Ideal Implant Inc | Series A | $16.8M | $49.4M | 1.00× |
| ExplORer Surgical Corp. | Series A | $11.2M | $45.9M | 0.93× |
| Nanomedical Diagnostics, Inc. | Series A | $12.0M | $38.0M | 0.77× |
| Precise Light Surgical, Inc. | Series A | $14.2M | $35.2M | 0.71× |
| Prescient Surgical, Inc. this company | Series A | $15.6M | $3.5M | 0.07× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $250K | 2013-04-12 | $1.4M | $9.2M | 85% |
| Seed | $3.9M | 2014-09-19 | $19.7M | $116.8M | 85% |
| Series A | $6.0M | 2014-09-19 | $27.3M | $145.1M | 85% |
| Series A | $1.5M | 2017-03-08 | $6.8M | $36.2M | 90% |
| Series A | $7.6M | 2018-10-26 | $34.6M | $183.8M | 90% |
| Series A | $250K | 2021-11-19 | $1.1M | $3.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Brant Heise | — | 9 other | 2017-03 |
| Eugene Chen | — | 8 other | 2017-03 |
| James DeStephens | — | 1 other | 2021-11 |
| Ann Sissel | — | — | 2018-10 |
| Brant T. Heise | — | — | 2014-09 |
| Eugene T. Chen | — | — | 2014-09 |
| Ferolyn Powell | — | — | 2013-04 |
| Ferolyn T. Powell | — | — | 2014-09 |
| Greg Bakan | — | — | 2018-10 |
| Jonathan Coe | — | — | 2013-04 |
| Joseph Tartaglia | — | — | 2013-04 |
| Robert T. White | — | — | 2014-09 |
Prescient Surgical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| New View Surgical, Inc. | Medical Devices | Series A | $15.8M | $70.8M | same sector · same stage |
| Ideal Implant Inc | Medical Devices | Series A | $16.8M | $49.4M | same sector · same stage |
| Pristine Surgical LLC | Medical Devices | Series A | $14.2M | $201.7M | same sector · same stage |
| Precise Light Surgical, Inc. | Medical Devices | Series A | $14.2M | $35.2M | same sector · same stage |
| Sandstone Diagnostics Inc | Medical Devices | Series A | $14.0M | $52.0M | same sector · same stage |
| Bayou Surgical, Inc. | Medical Devices | Series A | $13.2M | $14.8M | same sector · same stage |
| Black Light Surgical, Inc. | Medical Devices | Series A | $12.9M | $6.9M | same sector · same stage |
| Medite Cancer Diagnostics, Inc. | Medical Devices | Series A | $12.4M | $21.0M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Precisian Medical Instruments, Inc. | Healthtech | Pre-Seed | $528K | 85% |
| ReadySet Surgical, Inc. | Medical Devices | Series A | $7.6M | 84% |
| PreveCeutical Medical Inc. | Healthtech | Pre-Seed | $4.9M | 84% |
| SafeOp Surgical, Inc. | Medical Devices | Series A | $136.4M | 84% |
| Surgical Safety Technologies Inc. | Medical Devices | Series B | $70.3M | 83% |
| Specialty Surgical Center, LLC | Hospitals and Physicians | Seed | $18.3M | 83% |
| Think Surgical, Inc. | Medical Devices | Series D+ | $88.5M | 83% |
| SafeGuard Surgical, Inc. | Medical Devices | Seed | $5.9M | 83% |
See where Prescient Surgical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Prescient Surgical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.